Resolutions passed at the Extraordinary General Meeting
February 15, 2022 12:15 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
Amendment of proposals put forward at the Extraordinary General Meeting
February 14, 2022 16:01 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 04/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the...
Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States
February 11, 2022 01:50 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor newsNo. 02/2022www.orphazyme.comCompany Registration No. 32266355 Orphazyme has made progress towards resubmission of the NDA for arimoclomol to the FDA and plans to request a...
Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™
February 07, 2022 06:22 ET
|
ORPHAZYME A/S
Orphazyme A/SInvestor NewsNo. 01/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 7, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a...
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEO
January 31, 2022 11:00 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 03/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 31, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme”...
Notice to convene Extraordinary General Meeting
January 24, 2022 16:15 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 02/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 24, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a...
Orphazyme updates 2021 financial outlook
January 18, 2022 16:15 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 01/2022Inside information Company Registration No. 32266355 Net revenue range narrowed to DKK 35 – 37 millionOperating expenses lowered to DKK 665 – 675...
Orphazyme announces changes to the Board of Directors
December 09, 2021 00:45 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcementNo. 27/2021Company Registration No. 32266355 Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical...
Financial Calendar 2022
November 19, 2021 03:06 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 26/2021www.orphazyme.comCompany Registration No. 32266355 Copenhagen – November 19, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a...
Orphazyme establishes a U.S. At-the-Market Offering Program with Cowen
November 04, 2021 08:22 ET
|
ORPHAZYME A/S
Orphazyme A/SCompany announcement No. 25/2021Company Registration No. 32266355 Copenhagen – November 4, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical...